格隆汇9月12日丨蔚蓝生物(603739.SH)在投资者互动平台表示，公司没有H5N1和其他高致病禽流感亚 型的疫苗产品。公司兽用生物制品主要为各类疫苗、抗体，用于预防与控制家禽、家畜对流行疾病疫情 的感染。其中针对禽流感的产品主要包括禽流感（H9亚型）二联灭活疫苗、禽流感（H9亚型）三联灭 活疫苗、禽流感（H9亚型）四联灭活疫苗等。 ...

Group 1: Research Basic Information - The research object is Weilan Biology, belonging to the animal husbandry, feed and fishery industry, and the reception time was on September 4, 2025. The listed company's reception staff included the chairman and general manager Chen Gang, the director and financial controller Qiao Piyuan, the board secretary Jiang Yong, and independent directors Lin Yingtin and Wang Jing [17] Group 2: Detailed Research Institutions - The reception objects include investors' online questions and others [20] Group 3: Main Content - In the field of biocatalytic enzymes, the company continuously promotes technological innovation, provides comprehensive technical support for the brewing industry, enhances product quality and flavor, optimizes production, and promotes the high - value utilization of brewing by - products to support the industry's sustainable development [24] - The Weilan Biotechnology Center, the plant probiotic preparation project, and the animal health industry park of the company have been put into production and operation. The construction project of the refined enzyme series product production line of Weifang Kangdien also reached the预定可使用状态 in August 2025, completing the systematic production capacity layout of each business segment [25] - The company builds an "industry + service" comprehensive empowerment platform around the animal health strategy, providing systematic solutions covering animal nutrition, healthy breeding, and animal disease prevention and control. It has established a health - breeding process service platform, a raw material value evaluation and quality control service system, and a VLAND - PCP product precise customization platform, which has formed an enzyme - using database covering more than a hundred feed raw materials and has been highly recognized by many core customers [27] - The company adheres to the "talent first" development strategy, has a standardized management system in employee recruitment, training, incentives, and promotion, and has a stable and professional talent team with 36 doctors and 259 full - time R & D personnel. It also has good cooperation with universities, research institutes, and other enterprises [28] - In the first half of 2025, the company's R & D investment was 63.8829 million yuan, accounting for 9.80% of the operating income, with a year - on - year increase of 16.04%, maintaining a relatively high level in the industry [29]

Investment Rating - The report maintains a "Recommended" rating for the company [3][5]. Core Viewpoints - The company achieved a revenue of 652 million yuan in the first half of 2025, representing a year-on-year growth of 7.05%. However, the net profit attributable to the parent company decreased by 8.98% to 27 million yuan [1]. - The company has focused on innovation and increased its R&D investment to 64 million yuan, accounting for 9.80% of revenue, which is a 16.04% increase year-on-year [2]. - The company has completed its capacity layout, with various projects now in operation, enhancing its competitive edge and collaborative development across multiple business lines [3]. - The enzyme and probiotic industries have high barriers to entry, and the company is well-positioned as a representative player in these fields, with significant technological and platform advantages [3]. Financial Summary - The company expects net profits attributable to the parent company to be 74 million yuan, 81 million yuan, and 90 million yuan for the years 2025, 2026, and 2027, respectively [3]. - Earnings per share (EPS) are projected to be 0.29 yuan, 0.32 yuan, and 0.35 yuan for the same years, with corresponding price-to-earnings (PE) ratios of 50X, 46X, and 42X [3]. - Revenue is forecasted to grow from 1,431 million yuan in 2025 to 1,705 million yuan in 2027, with growth rates of 8.4%, 8.9%, and 9.4% respectively [9].

Core Viewpoint - The recent financial report of Weilan Bio (603739) shows mixed results, with revenue growth but a decline in net profit, raising concerns about cash flow and accounts receivable management [1][3]. Financial Performance - Total revenue for the first half of 2025 reached 652 million yuan, a year-on-year increase of 7.05% [1]. - Net profit attributable to shareholders was 26.72 million yuan, down 8.98% year-on-year [1]. - In Q2 2025, revenue was 342 million yuan, up 6.06% year-on-year, while net profit for the quarter was 17.14 million yuan, an increase of 3.07% [1]. Profitability Metrics - Gross margin stood at 45.07%, reflecting a slight increase of 0.67% year-on-year [1]. - Net margin decreased to 6.1%, down 12.12% year-on-year [1]. - Earnings per share (EPS) was 0.11 yuan, a decline of 8.33% compared to the previous year [1]. Cash Flow and Debt Management - Operating cash flow per share dropped significantly to 0.04 yuan, a decrease of 80.6% year-on-year [1]. - The ratio of cash and cash equivalents to current liabilities was only 43.42%, indicating potential liquidity issues [3]. - Interest-bearing debt decreased to 638 million yuan, down 20.27% year-on-year [1]. Accounts Receivable Concerns - Accounts receivable increased to 379 million yuan, a rise of 15.63% year-on-year, with accounts receivable to net profit ratio reaching 604.74% [1][3]. - The company’s historical return on invested capital (ROIC) was 4.45%, indicating weak capital returns [3].

Fundraising Overview - The company raised a total of RMB 394,016,730.00 from its initial public offering (IPO) by issuing 38,667,000 shares at RMB 10.19 per share, with a net amount of RMB 347,440,291.00 after deducting issuance costs [1][2] - For the non-public offering, the company raised RMB 499,999,984.00 at a price of RMB 19.69 per share, resulting in a net amount of RMB 495,954,700.96 after deducting issuance costs [2][3] Fund Management - The company has established a fundraising management method to ensure the proper management and use of raised funds, in compliance with relevant laws and regulations [3][4] - The company has signed tripartite supervision agreements with banks to manage the special accounts for the raised funds [5][8] Fund Usage - As of June 30, 2025, the company has used RMB 346,338,200.00 from the IPO funds and RMB 498,098,300.00 from the non-public offering funds [10][12] - The company has not used any idle funds for temporary working capital or for cash management during the reporting period [11][13] Project Changes - The company has made changes to its fundraising projects, including reallocating unused funds from the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project to new projects [14][15][16] - The company has also approved the completion of certain projects and the permanent allocation of surplus funds to working capital [12][13] Disclosure Compliance - The company has complied with the disclosure requirements set by the China Securities Regulatory Commission, ensuring timely and accurate reporting of the fundraising and usage status [17]

Group 1 - The board meeting of Qingdao Weilan Biological Co., Ltd. was held on August 27, 2025, with all five directors present, ensuring compliance with relevant regulations [1][2] - The meeting's resolutions were deemed legal and effective, following the procedures outlined in the Company Law of the People's Republic of China and the company's articles of association [1] - The board approved the special report on the use of raised funds, with unanimous support from all directors present [2] Group 2 - The meeting was convened after prior approval from the company's audit committee, indicating a structured decision-making process [2] - All votes during the meeting were in favor, with no dissenting or abstaining votes recorded [2] - Detailed information regarding the half-year report and the special report on fund usage can be found on the Shanghai Stock Exchange website [1][2]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-037 青岛蔚蓝生物股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》及相关格式指引的规定，青岛蔚蓝生物股份有限公 司（以下简称"公司"）现将 2025 年半年度募集资金存放与实际使用情况专项说 明如下： 一、募集资金基本情况 （一）首次公开发行募集资金 经中国证券监督管理委员会证监许可[2018]1961 号文核准，公司向社会公 众公开发行人民币普通股(A 股)股票 3,866.70 万股，发行价为每股人民币 10.19 元，共计募集资金 394,016,730.00 元，扣除各项发行费用后，实际募集资金净 额为人民币 347,440,291.00 元。上述募集资金已于 2019 年 1 月 9 日到位，已经 瑞华会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》(瑞华验字 [2019]37110002 号)。公司对募集资金实行专户存储。 明细 金 ...

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. disclosed its major operational data for Q2 2025, highlighting significant revenue figures and changes in distributor numbers, which provide insights into the company's performance and market dynamics [1]. Group 1: Operational Performance - The total revenue for Q2 2025 amounted to CNY 255,554,845.37, with enzyme preparations contributing CNY 118,822,845.82 and micro-ecological preparations contributing CNY 62,179,855.65 [1]. - Direct sales accounted for CNY 171,922,085.69, while distribution sales totaled CNY 83,632,759.68 [1]. - Domestic sales reached CNY 224,210,819.54, while overseas sales were CNY 31,344,025.83 [1]. Group 2: Distributor Changes - The total number of distributors increased from 545 to 636 during the reporting period, indicating a growth in the distribution network [1]. - In Northeast China, the number of distributors rose from 31 to 38, while in North China, it increased from 60 to 76 [1]. - The East China region saw a significant increase from 304 to 331 distributors, while South China had a slight increase from 50 to 55 [1].

Core Viewpoint - The company, Qingdao Vland Biotech Group Co., Ltd., is set to hold a half-year performance briefing on September 4, 2025, to discuss its operational results and financial status for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting will take place on September 4, 2025, from 9:00 AM to 10:00 AM [1][2]. - It will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: http://roadshow.sseinfo.com/ [1][2]. - The format of the meeting will be an interactive online session [1][2]. Group 2: Participation Information - Investors can submit questions from August 28, 2025, to September 3, 2025, before 4:00 PM through the Roadshow Center's "Question Pre-collection" section or via the company's email [2][3]. - The company will address commonly asked questions during the briefing [2][3]. Group 3: Attendees - Key attendees include the Chairman and General Manager, Chen Gang; the Director and Chief Financial Officer, Qiao Piyuan; the Secretary of the Board, Jiang Yong; and independent directors Wang Jing and Lin Yingtian [2]. Group 4: Contact Information - For inquiries, investors can contact Jiang Yong at phone number 0532-88978071 or via email at vland@vlandgroup.com [3]. Group 5: Post-Meeting Access - After the meeting, investors can view the meeting's proceedings and main content on the Shanghai Stock Exchange Roadshow Center website [3].

Core Insights - The company reported a revenue of 652 million yuan for the first half of 2025, representing a year-on-year increase of 7.05% [1] - The net profit attributable to shareholders decreased by 8.98% to 26.72 million yuan [1] - The net profit excluding non-recurring items was 16 million yuan, showing a year-on-year growth of 4.17% [1] - The basic earnings per share stood at 0.11 yuan [1]